Concord Biotech
Concord Biotech Share Price Chart
Concord Biotech last traded at ₹1,354.60 (2026-10-13). Over the past month the stock moved -6.4%, three months the stock moved +18.9%, year the stock moved -13.5%. Its closing range over 52 weeks is ₹1,014.80 – ₹1,575.00, with the latest close 14.0% below the high.
Closing prices up to 2026-10-13.
About Concord Biotech
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
Business Profile[1] Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Concord Biotech reported sales of ₹261.00 crore (+27.9%) and net profit of ₹61.00 crore (+41.9%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 261.00 | 87.00 | 33.00 | 61.00 | 5.85 |
| Mar 2026 | 326.00 | 122.00 | 38.00 | 90.00 | 8.60 |
| Dec 2025 | 278.00 | 102.00 | 37.00 | 68.00 | 6.48 |
| Sep 2025 | 247.00 | 91.00 | 37.00 | 63.00 | 6.01 |
| Jun 2025 | 204.00 | 61.00 | 30.00 | 43.00 | 4.07 |
| Mar 2025 | 430.00 | 190.00 | 44.00 | 142.00 | 13.57 |
| Dec 2024 | 244.00 | 98.00 | 40.00 | 74.00 | 7.08 |
| Sep 2024 | 310.00 | 137.00 | 44.00 | 99.00 | 9.43 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +18.3% | +1.2% | +34.8% | -5.6% | -20.3% | +13.9% | -24.2% | +27.9% |
| Operating profit growth | +15.1% | -7.5% | +41.8% | -24.7% | -33.6% | +4.1% | -35.8% | +42.6% |
| Net profit growth | +17.9% | -1.3% | +46.4% | -25.9% | -36.4% | -8.1% | -36.6% | +41.9% |
| EPS growth | +16.7% | -0.7% | +46.1% | -26.9% | -36.3% | -8.5% | -36.6% | +43.7% |
| OPM % | 44.0% | 40.0% | 44.0% | 30.0% | 37.0% | 37.0% | 38.0% | 33.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Concord Biotech reported sales of ₹1,055.00 crore (-12.1%) and net profit of ₹263.00 crore (-29.3%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 1,055 | 377.00 | 36.00 | 263.00 | 25.17 |
| Mar 2025 | 1,200 | 505.00 | 42.00 | 372.00 | 35.52 |
| Mar 2024 | 1,017 | 432.00 | 42.00 | 308.00 | 29.45 |
| Mar 2023 | 853.00 | 344.00 | 40.00 | 240.00 | 22.95 |
| Mar 2022 | 713.00 | 270.00 | 38.00 | 175.00 | 183.93 |
| Mar 2021 | 616.00 | 327.00 | 53.00 | 235.00 | 247.44 |
| Mar 2020 | 512.00 | 205.00 | 40.00 | 169.00 | 177.81 |
| Mar 2019 | 436.00 | 180.00 | 41.00 | 118.00 | 124.48 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +28.2% | +17.4% | +20.3% | +15.7% | +19.6% | +19.2% | +18.0% | -12.1% |
| Operating profit growth | +41.7% | +13.9% | +59.5% | -17.4% | +27.4% | +25.6% | +16.9% | -25.3% |
| Net profit growth | +18.0% | +43.2% | +39.1% | -25.5% | +37.1% | +28.3% | +20.8% | -29.3% |
| EPS growth | +17.8% | +42.8% | +39.2% | -25.7% | -87.5% | +28.3% | +20.6% | -29.1% |
| OPM % | 41.0% | 40.0% | 53.0% | 38.0% | 40.0% | 42.0% | 42.0% | 36.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Concord Biotech.
Get Free AI Stock Analysis FREE →Latest News
-
Concord Biotech board nods for bonus issue, authorised capital increase to ₹22 crore
-
Concord Biotech 1:1 bonus issue announced! Jhunjhunwala family-backed stock up 50% in 6 months— record date, details
-
Concord Biotech board nods for bonus issue, authorised capital increase to ₹22 crore
-
Concord Biotech 1:1 bonus issue: Jhunjhunwala family-backed pharma stock gains 50% in 6 months, check record date detail
-
Concord Biotech shares surge 5% as board to meet on September 23 to consider bonus issue
-
Concord Biotech bonus issue sparks rally! Pharma stock jumps 6% on maiden share reward - Top things to know
-
Concord Biotech shares surge 5% as board to meet on September 23 to consider bonus issue
-
USFDA completes inspection at Concord Biotech’s formulation facility in Gujarat
-
Concord Biotech Base Case Target Achieved
-
Concord Biotech clears PPB Kenya, NDA Uganda inspection at Unit-II formulation facility
Frequently Asked Questions
What is Concord Biotech's current stock price?
Concord Biotech shares were last quoted at ₹1,354.60 (-0.5% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Concord Biotech?
Concord Biotech has a price-to-earnings (P/E) ratio of 55.25 and a price-to-book (P/B) ratio of 7.34. The industry P/E is 53.33.
What is the 52-week high and low of Concord Biotech?
The 52-week high of Concord Biotech is ₹1,667.00 and the 52-week low is ₹987.05.
What is the market cap of Concord Biotech?
The market capitalisation of Concord Biotech is about ₹15,213.29 crore.
How did Concord Biotech perform in its latest quarterly results?
In the latest quarter (Jun 2026), Concord Biotech reported sales of ₹261.00 crore (+27.9%) and net profit of ₹61.00 crore (+41.9%), compared with the same quarter last year.
Is Concord Biotech a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Concord Biotech has a 3-year ROE of 18.00%, 3-year profit growth of 1.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Concord Biotech?
Promoters hold about 44.08% of Concord Biotech.
Which sector does Concord Biotech belong to?
Concord Biotech belongs to the Biotechnology & Medical Research sector.
Other Biotechnology & Medical Research stocks
- Biocon
- Sun Pharma Advanced Research Company
- Windlas Biotech
- Arvee Laboratories
- Softrak Venture Investment
- ANG Lifesciences India
- Vivo Biotech
- Genomic Valley Biotech
All Biotechnology & Medical Research stocks · Browse all stocks A–Z